In April, aging research expert Norman E. (Ned) Sharpless, MD will become the acting commissioner of the Food and Drug Administration. Dr. Sharpless is a 2003 Paul B. Beeson Emerging Leaders Career Development Award in Aging scholar. Ned served on AFAR’s National Scientific Advisory Council from 2005-2011 and chaired the Selection Committee of the Glenn/AFAR Postdoctoral Program for Transnational Research on Aging program in 2015 and 2016. For over 30 years, AFAR has supported the science of healthier aging.
Metforming Aging TrialAFAR has raised $35 million out of a needed $55 million for the Targeting Aging with Metformin Trial. There would still be the need for the NIH (National Institute of Health) to contribute another $40 million for the study. Dr. Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine, designed the Targeting Aging with Metformin anti-aging study. Metformin is an antidiabetic drug that was approved by the FDA more than 70 years ago. It is estimated that 120 million people take metformin. It has been shown to extend the lives of nematodes by 57% and mice by 6%. TAME will consist of 3,000 patients between 65 – 79 years old and have a composite primary endpoint of myocardial infarction, stroke, heart failure, cancer, dementia and death. The trial could detect 22.5% reduced incidences of those diseases. SOURCES- AFAR, New York Times, FDA, Nature Written By Brian Wang, Nextbigfuture
Brian Wang is a prolific business-oriented writer of emerging and disruptive technologies. He is known for insightful articles that combine business and technical analysis that catches the attention of the general public and is also useful for those in the industries. He is the sole author and writer of nextbigfuture.com, the top online science blog. He is also involved in angel investing and raising funds for breakthrough technology startup companies.
He gave the recent keynote presentation at Monte Jade event with a talk entitled the Future for You. He gave an annual update on molecular nanotechnology at Singularity University on nanotechnology, gave a TEDX talk on energy, and advises USC ASTE 527 (advanced space projects program). He has been interviewed for radio, professional organizations. podcasts and corporate events. He was recently interviewed by the radio program Steel on Steel on satellites and high altitude balloons that will track all movement in many parts of the USA.
He fundraises for various high impact technology companies and has worked in computer technology, insurance, healthcare and with corporate finance.
He has substantial familiarity with a broad range of breakthrough technologies like age reversal and antiaging, quantum computers, artificial intelligence, ocean tech, agtech, nuclear fission, advanced nuclear fission, space propulsion, satellites, imaging, molecular nanotechnology, biotechnology, medicine, blockchain, crypto and many other areas.